<PAGE>
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 10-Q
[X] QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE
ACT OF 1934
FOR QUARTER ENDED MARCH 31, 2000
OR
[ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES
EXCHANGE ACT OF 1934
FOR THE TRANSITION PERIOD FROM __________TO__________
Commission file number 33-90516
---------
NEOPHARM, INC.
(EXACT NAME OF REGISTRANT AS SPECIFIED IN ITS CHARTER)
Delaware 51-0327886
(State or other jurisdiction of (I.R.S. Employer
incorporation or organization) Identification Number)
100 Corporate North
Suite 215
Bannockburn, Illinois 60015
(Address of principal executive offices) (Zip Code)
(847) 295-8678
(Registrant's telephone number, including area code)
Indicate by check mark whether the registrant (1) has filed all reports
required to be filed by Section 13 or 15(d) of the Securities Exchange Act
of 1934 during the preceding 12 months (or for such shorter period that the
registrant was required to file such reports), and (2) has been subject to
such filing requirements for the past 90 days. Yes _X_ No __ .
Indicate the number of shares outstanding of each of the issuer's classes
of common stock, as of the close of the period covered by this report:
Title of each class Number of shares outstanding
------------------- ----------------------------
Common Stock ($.0002145 par value) 11,130,406
<PAGE>
NEOPHARM, INC.
(A DELAWARE CORPORATION)
<TABLE>
<CAPTION>
Page Number
-----------
<S> <C> <C>
PART I. Financial Information
ITEM 1. Financial Statements
Balance Sheets 3
Statements of Operations 4
Statements of Cash Flows 5
Notes to Financial Statements 6
ITEM 2. Management's Discussion and Analysis of
Financial Condition and Results of Operations 8
PART II. Other Information 12
SIGNATURE PAGE 13
</TABLE>
2
<PAGE>
PART I - FINANCIAL INFORMATION
ITEM 1 - FINANCIAL STATEMENTS
NEOPHARM, INC.
(A DELAWARE CORPORATION)
BALANCE SHEETS
(Unaudited)
<TABLE>
<CAPTION>
MARCH 31, DECEMBER 31,
2000 1999
<S> <C> <C>
ASSETS
Current assets:
Cash and cash equivalents $ 26,668,949 $ 24,664,567
Other receivables 555 76,007
Tax refund receivable 126,000 126,000
Prepaid expenses 214,407 118,800
------------ -----------
Total current assets $27,009,911 $24,985,374
Equipment and furniture:
Equipment 85,447 85,447
Furniture 80,210 80,210
Less accumulated depreciation (105,252) (99,283)
------------ -----------
Total equipment and furniture, net 60,405 66,374
Total assets $ 27,070,316 $ 25,051,748
------------ ------------
------------ ------------
LIABILITIES AND STOCKHOLDERS' EQUITY
Current liabilities:
Obligations under research agreements $ 103,333 $ 68,333
Accounts payable 313,389 567,357
Accrued compensation 61,890 296,000
Other accrued expenses 78,317 115,000
------ -------
Total current liabilities $ 556,929 $ 1,046,690
----------- ---------
Stockholders' equity:
Common stock, $.0002145 par value;
15,000,000 shares authorized:
11,130,406 and 11,028,617 shares issued
and outstanding, respectively 2,388 2,366
Additional paid-in capital 25,962,895 25,709,261
Accumulated earnings/(deficit) 548,104 (1,706,569)
-------- -----------
Total stockholders' equity $26,513,387 $24,005,058
------------ ------------
Total liabilities and stockholders'
equity $ 27,070,316 $ 25,051,748
------------ ------------
------------ ------------
</TABLE>
The accompanying notes are an integral part of these balance sheets.
3
<PAGE>
NEOPHARM, INC.
(A DELAWARE CORPORATION)
STATEMENT OF OPERATIONS
THREE MONTHS ENDED MARCH 31, 2000 AND 1999
(Unaudited)
<TABLE>
<CAPTION>
MARCH 31, MARCH 31,
2000 1999
---- ----
<S> <C> <C>
Revenues $3,000,000 $9,000,000
Expenses:
Research and development 519,081 606,999
General and administrative 497,483 588,738
Related party expenses (Note 3) 141,936 902,691
------------ ------------
Total Expenses 1,158,500 2,098,428
Income from operations 1,841,500 6,901,572
Interest income 413,173 35,007
Interest expense - principal shareholder - 1,062
Interest expense - other - 798
------------ ------------
Interest income(expense) - net 413,173 33,147
Net Income before income taxes $ 2,254,673 $ 6,934,719
------------ ------------
------------ ------------
Income taxes - 2,774,000
------------ ------------
Net Income $2,254,673 $4,160,719
------------ ------------
Net Income per share
Basic $ .20 $ .49
------------ ------------
Diluted $ .19 $ .38
------------ ------------
Weighted average shares outstanding
Basic 11,054,798 8,417,622
------------ ------------
Diluted 11,972,088 11,059,752
------------ ------------
</TABLE>
The accompanying notes are an integral part of these financial statements.
4
<PAGE>
NEOPHARM, INC.
(A DELAWARE CORPORATION)
STATEMENT OF CASH FLOWS
THREE MONTHS ENDED MARCH 31, 2000 AND 1999
(Unaudited)
<TABLE>
<CAPTION>
MARCH 31, MARCH 31,
2000 1999
---- ----
<S> <C> <C>
Cash flows from operating activities:
Net income $ 2,254,673 $ 4,160,719
Adjustments to reconcile net income to
net cash provided by operating activities:
Depreciation and amortization 5,969 8,999
Deferred income taxes - 2,739,000
Compensation expense from non-employee
stock options 78,556 -
Restricted stock grants in lieu of
cash compensation 15,750 -
Increase in other assets (20,155) (319,688)
(Decrease)/Increase in accounts
payable and accrued liabilities (489,761) 587,660
------------- -----------
Net cash provided by operating activities 1,845,032 7,176,690
------------- -----------
Cash flows used in investing activities:
Purchase of equipment and
furniture - (725)
------------- -----------
Net cash used in investing activities - (725)
------------- -----------
Cash flows from financing activities:
Proceeds from issuance of common stock 159,350 182,000
Proceeds from exercise of warrants - 3,402
Cashless exercise of warrants, charge (1,844,314) (1,019,104)
Cashless exercise of warrants, proceeds 1,844,314 1,019,104
------------- -----------
Net cash and cash equivalents
provided by financing activities 159,350 185,402
------------- -----------
Net increase in cash 2,004,382 7,361,367
Cash and cash equivalents, beginning
of period 24,664,567 40,681
------------- -----------
Cash and cash equivalents, end of period $ 26,668,949 $ 7,402,048
------------- -----------
------------- -----------
Supplemental disclosure of cash paid for:
Interest $ - $ 1,860
Income taxes $ - $ -
------------- -----------
</TABLE>
The accompanying notes are an integral part of these financial statements.
5
<PAGE>
NEOPHARM, INC.
(A DELAWARE CORPORATION)
NOTES TO FINANCIAL STATEMENTS
MARCH 31, 2000
NOTE 1 BASIS OF PRESENTATION
The financial information herein is unaudited, other than the Balance Sheet at
December 31, 1999, which is derived from the audited financial statements.
The accompanying unaudited interim financial statements of NeoPharm, Inc. (the
"Company") have been prepared in accordance with generally accepted accounting
principles for interim financial information and with the instructions to Form
10-Q and Rule 10-01 of Regulation S-X. Accordingly, they do not contain all of
the information and footnotes required by generally accepted accounting
principles for complete financial statements. In the opinion of the Company, the
accompanying unaudited interim financial statements contain all adjustments
(consisting of normal recurring adjustments) necessary to present fairly the
Company's financial position as of March 31, 2000, the results of operations for
the three months ended March 31, 2000 and 1999, the changes in cash flows for
the three month periods ended March 31, 2000 and 1999.
While the Company believes that the disclosures presented are adequate to make
the information not misleading, it is suggested that these financial statements
be read in conjunction with the financial statements and notes included in the
Company's 1999 Annual Report on Form 10-K filed with the Securities and Exchange
Commission.
NOTE 2 EARNINGS PER SHARE
The following table sets forth the computation of the basic and diluted earnings
per share from continuing operations:
<TABLE>
<CAPTION>
For the three months ended:
---------------------------
March 31 March 31
2000 1999
--------- -------
<S> <C> <C>
Numerator:
Net income from continuing operations $ 2,254,673 $ 4,160,719
----------- -----------
----------- -----------
Denominator:
Denominator for basic income per share-weighted
average shares 11,054,798 8,417,622
Effect of Dilutive securities:
Stock options 868,511 1,358,294
Warrant exercise 48,779 1,283,836
----------- -----------
Dilutive potential common shares 917,290 2,642,130
----------- -----------
----------- -----------
Denominator for diluted income per share-weighted
Average shares and assumed conversions 11,972,088 11,059,752
----------- -----------
----------- -----------
Basic income per share $ .20 $ .49
----------- -----------
----------- -----------
Diluted income per share $ .19 $ .38
----------- -----------
----------- -----------
</TABLE>
6
<PAGE>
NOTE 3 RELATED PARTY EXPENSES
The following table provides further detail of the related party
expenses reflected in the statement of operations:
<TABLE>
<CAPTION>
For the three months ended:
---------------------------
March 31, March 31,
Related Party Expense Type 2000 1999
-------- --------
<S> <C> <C>
Georgetown University Research & Fees $ 98,483 $800,000
Gail Salzberg Consulting 2,323 60,705
E.J. Financial Enterprises Consulting 31,250 31,250
E.J. Financial Enterprises Direct Expenses 1,689 1,480
-------- --------
Total research and development expenses 133,745 893,435
Option Care, Inc.Rent and Expenses 8,191 9,256
-------- --------
Total general and administrative expenses 8,191 9,256
-------- --------
Total related party expenses $141,936 $902,691
-------- --------
-------- --------
</TABLE>
Management believes that the terms of the related party transactions listed
above were at fair market rates.
7
<PAGE>
ITEM 2 - MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS
OF OPERATIONS
Any statements made by NeoPharm Inc. ("we", "us", "our" or the "Company") in
this quarterly report that are forward looking are made pursuant to the safe
harbor provisions of the Private Securities Litigation Reform Act of 1995.
Readers are cautioned that important factors may affect our actual results and
could cause such results to differ materially from forward-looking statements
made by us or on our behalf. Such factors include, but are not limited to,
changing market conditions, the impact of competitive products and pricing, the
timely development, approval by the Food and Drug Administration ("FDA") and
foreign health authorities, and market acceptance of our products in
development, our ability to further raise capital, our dependence on key
personnel, and other factors referenced under "Risk Factors" in our Annual
Report on Form 10-K for the fiscal year ended December 31, 1999.
OVERVIEW
We are a biopharmaceutical company engaged in the research and
development and commercialization of drugs for the treatment of various
cancers. We currently have a portfolio of seven anti-cancer drugs, three of
which are in clinical trials. We have built our drug portfolio based on our
two novel proprietary technology platforms: a liposomal drug delivery
platform and a tumor-targeting platform. In February 1999, we entered into a
collaboration agreement with Pharmacia Corporation ("PNU"), to develop and
commercialize our two leading products: liposome encapsulated doxorubicin, or
LED, and liposome encapsulated paclitaxel, or LEP. In conjunction with PNU,
we have initiated multi-center Phase II/III clinical trials of LEP for the
treatment of a variety of cancers, including breast, ovarian and lung
cancers, and we are currently conducting multi-center Phase II/III clinical
trials for LED for the treatment of breast and prostate cancers.
In addition to LEP and LED, we have five other products under
development. Under our liposomal platform, we are preparing to file an
investigational new drug application for LE-AON, our liposome encapsulated gene
inhibitor for radiation resistant tumors, and we have initiated preclinical
studies for liposomal encapsulated epirubicin, or LEE, and liposomal
encapsulated mitoxantrone, or LEM. Under our tumor-targeting platform, we are
currently in a Phase I/II clinical trial for IL13-PE38, a tumor-targeting
product for the treatment of kidney cancer. In March 2000, we filed an
investigational new drug application for our other tumor-targeting product, SS1
(ds Fv)-PE38, and we expect to commence Phase I/II clinical trials for SS1 (ds
Fv)-PE38 for the treatment of various cancers in the second quarter of 2000.
OUR PRODUCTS
We have utilized both our liposomal platform and our tumor-targeting platform to
develop a group of novel anti-cancer products. Presently, we have three products
in clinical trials and four in preclinical trials.
LIPOSOMAL PLATFORM
LIPOSOME ENCAPSULATED PACLITAXEL
PRODUCT DESCRIPTION. LEP is a liposome encapsulated formulation of the
widely-used cancer drug, paclitaxel. Paclitaxel is marketed by Bristol-Myers
Squibb Company under the trade name "Taxol(R)" and is used in the treatment of a
number of tumors, including breast and lung cancer. Despite paclitaxel's wide
use and its anti-tumor characteristics, its effectiveness is limited by its side
effects, which can include nausea, vomiting, hair loss and nerve and muscle
pain. The low solubility of paclitaxel necessitates formulation in a toxic
mixture of castor oil and ethanol which requires premedication. In addition,
paclitaxel must be infused over a period of at least three hours.
We believe we have overcome many of the current limitations of
paclitaxel by utilizing cardiolipin, a naturally occurring negatively charged
lipid found in cardiac tissue, to increase the solubility of paclitaxel, thus
eliminating the need for administration of castor oil and ethanol and the
accompanying premedication. Since paclitaxel has a positive charge and
cardiolipin has a negative charge, cardiolipin combines with the paclitaxel to
form a stable product that can be freeze dried and easily reconstituted. We have
been able to standardize the preparation of cardiolipin through the development
of a proprietary form of synthetic cardiolipin. Based on preclinical studies, we
believe another potential advantage of LEP is the ability of cardiolipin to
overcome the resistance to cancer drugs developed by cells which have
8
<PAGE>
been exposed to several rounds of chemotherapy. As a result, the cytotoxicity of
LEP against tumors increases significantly, maximizing the killing of otherwise
resistant cells.
DEVELOPMENT STATUS. We believe LEP is the first, and only, liposomal form of
paclitaxel to enter clinical trials. We completed our Phase I clinical trials
in March 2000. These Phase I trials, which involved 29 advanced stage cancer
patients, confirmed that LEP could be administered at higher levels than
paclitaxel is currently administered, with fewer side effects. Six patients
have experienced tumor reductions greater than 35%. The tumors in eight other
patients did not increase in size after 12 weeks, and in four of these eight
patients, the tumors were still stable in size one year later. Some patients
received significantly more cycles of LEP than can be given with
unencapsulated paclitaxel, and no patients showed signs of the nerve and
muscle pain commonly associated with paclitaxel. Two patients have received
greater than 20 cycles of LEP. Most patients did not experience the hair loss
or nausea often associated with paclitaxel treatment.
Currently, our collaboration partner, PNU, is initiating large scale
multi-center, multinational Phase II/III clinical trials. These Phase II/III
trials will test LEP as both a single and combination therapy for a variety of
solid tumors to determine its safety and efficacy.
LIPOSOME ENCAPSULATED DOXORUBICIN
PRODUCT DESCRIPTION. LED is a liposome encapsulated formulation of the widely
used cancer drug, doxorubicin. Doxorubicin is used to treat a number of cancers
including solid tumors and leukemia, a form of blood cancer. Though effective in
treating these and other cancers, doxorubicin may produce irreversible heart
damage. The risk of heart failure increases with increasing total cumulative
doses of doxorubicin. Doxorubicin also causes suppression of white blood cell
production, which may be dose limiting, and produces side effects such as
nausea, vomiting and hair loss. As we have done with LEP, we have diminished
these side effects by encapsulating doxorubicin using synthetic cardiolipin.
Since doxorubicin has a positive charge and cardiolipin has a negative charge,
cardiolipin combines with the doxorubicin to form a stable product that can be
freeze dried and easily reconstituted. We believe LED, unlike other liposomal
doxorubicin products currently available, will, because of its formulation with
cardiolipin, overcome the resistance to cancer drugs developed by cells which
have been exposed to several rounds of chemotherapy and will be easier to
manufacture.
DEVELOPMENT STATUS. In June 1998, we started Phase II clinical trials for the
treatment of advanced prostate cancer in 10 patients. After four rounds of
treatment, the level of prostate specific antigen, an indicator of the extent of
disease progression, decreased by greater than 35% in two patients and
stabilized in two other patients. These four patients reported a significant
reduction in pain. Our collaborative partner, PNU, is currently conducting
multi-center Phase II/III clinical trials of LED.
We completed a Phase I trial in May 1998, which confirmed that LED
demonstrated lower toxicity when compared to unencapsulated doxorubicin and
could be given at approximately double the current dose for doxorubicin.
LIPOSOME ENCAPSULATED ANTISENSE OLIGONUCLEOTIDES
PRODUCT DESCRIPTION. We have developed a liposome encapsulated antisense cRaf
oligonucleotide, LE-AON, which we believe inhibits the expression of the cRaf
protein and thus may have potential to enhance the effectiveness of radiation in
the treatment of certain cancers. cRaf is a protein which is expressed at higher
levels in cancer cells which are resistant to radiation therapy than in healthy
cells. By inhibiting expression of this gene, the cell becomes more susceptible
to radiation therapy. Our liposomes provide a non-viral method of delivering the
gene inhibitor into the cell. An additional advantage of LE-AON is that it can
be administered intravenously and is relatively easy to manufacture.
DEVELOPMENT STATUS. We have preclinical studies of LE-AON in progress designed
to enable us to undertake a Phase I clinical trial. In our preclinical studies,
intravenous administration of LE-AON inhibited cRaf gene expression in tumor
tissue. When LE-AON was given in combination with radiation treatment, tumor
regression for at least 27 days was observed.
9
<PAGE>
LIPOSOMAL ENCAPSULATED EPIRUBICIN
Epirubicin is a drug that is widely used in Europe for the treatment of
breast cancer and was recently introduced in the U.S. market by our
collaborative partner, PNU. We have recently encapsulated epirubicin in our
liposomes ("LEE") and intend to evaluate its properties as a treatment for
breast cancer.
LIPOSOMAL ENCAPSULATED MITOXANTRONE
We recently encapsulated mitoxantrone in our liposomes ("LEM").
Mitoxantrone is used for the treatment of prostate cancer and multiple
sclerosis. We believe LEM will demonstrate a safety and efficacy advantage over
unencapsulated mitoxantrone. Currently we are conducting preclinical studies to
evaluate the profile of this drug.
TUMOR-TARGETING PLATFORM
IL13-PE38
PRODUCT DESCRIPTION. IL13-PE38 is a tumor-targeting agent we are developing for
the treatment of kidney and brain cancers. Research by scientists at the FDA and
the NIH has demonstrated that some solid tumors express high numbers of IL13
receptors on their cell surfaces. IL13-PE38 links the cytotoxin PE38 to the
tumor-targeting agent IL13. When administered, IL13-PE38 targets the IL13
receptors, which are present in greater numbers in cancer cells than healthy
cells, and delivers the PE38 toxin to these cancer cells without harming the
healthy cells.
In October 1997, we entered into an exclusive worldwide licensing
agreement with the FDA and the NIH giving us rights to develop and commercialize
IL13-PE38. We also entered into a cooperative research and development agreement
with the FDA for the clinical and commercial development of IL13-PE38 as an
anti-cancer agent. We believe this is the first collaboration between the FDA
and a biopharmaceutical company.
DEVELOPMENT STATUS. In preclinical studies, IL13-PE38 has demonstrated tumor
regression in a number of cancers. We filed an investigational new drug
application for IL13-PE38 for the treatment of kidney cancer in June 1999 and
entered Phase I/II clinical trials in October 1999 for this indication. We filed
an investigational new drug application for brain cancer in March 2000 and
anticipate beginning Phase I/II clinical trials for brain cancer in the second
quarter of 2000.
SS1(dsFv)-PE38
PRODUCT DESCRIPTION. SS1(dsFv)-PE38 links the cytotoxin PE38 to the antibody
SS1(dsFv). As is the case with IL13, SS1(dsFv) targets specific receptors
on cancer cells and delivers the cytotoxin directly to the cancer cells
without effecting healthy cells. In March 1999, we executed a worldwide
exclusive licensing agreement with the NIH giving us rights to develop and
commercialize SS1(dsFv)-PE38. We also entered into a cooperative research
and development agreement with the NIH for the clinical and commercial
development of SS1(dsFv)-PE38 as an anti-cancer agent.
DEVELOPMENT STATUS. In April 2000, we filed an investigational new drug
application for SS1(dsFv)-PE38 for the treatment of certain common cancers and
expect to commence Phase I/II clinical studies in ovarian cancer, lung cancer,
and head and neck cancers in the second quarter of 2000. In preclinical studies,
SS1(dsFv)-PE38 demonstrated very specific targeting to receptors for ovarian
cancer and head and neck cancer and a high level of toxicity. Preclinical
studies have shown a complete response rate in ovarian tumors.
RESULTS OF OPERATIONS - THREE MONTHS ENDED MARCH 31, 2000 VS. THREE MONTHS ENDED
MARCH 31, 1999.
For the three months ended March 31, 2000, we received a $3,000,000 milestone
payment from PNU for completion of Phase I/ beginning of Phase II clinical
trials for LEP. We recorded a nonrefundable license fee of $9,000,000 for the
same period in 1999 related to the licensing agreement with PNU for the
development and commercialization of LEP and LED.
Research and development expense for the three months period ended March 31,
2000 were $652,826 compared to $1,500,434 for the same period in 1999. The
overall reduction in research and development costs was the result of
nonrecurring 1999 expenses associated with licensing of SS1(dsFv)-PE38 of
approximately $256,000 and a sublicense
10
<PAGE>
fee paid to Georgetown of $800,000 coupled with increased spending in 2000 of
approximately $208,000 primarily for the development of LEAON, SS1(dsFv)-PE38
and IL13-PE38.
General and administrative expenses for the three month period ended March 31,
2000 were $505,674 compared to $597,994 for the same period in 1999. The overall
reduction in general and administrative expenses was a result of reduced
professional fees of $92,000, a reduction in various other general and
administrative expenses of approximately $47,300 coupled with an increase in
franchise taxes of approximately $47,000. In the prior year period, we incurred
additional professional fees and administrative expenses in completing our
licensing agreement with PNU. The current year's increase in franchise taxes
resulted from the increase in our capitalization due to the sale of shares to
PNU and the conversion of our warrants into common stock following the calling
for redemption of our warrants.
We generated interest income on excess cash balances of $413,173 and $35,007 for
the three month periods ended March 31, 2000 and March 31, 1999 respectively.
We incurred $1,860 of interest expense for the three month period ended March
31, 1999. We incurred no interest expense during the current period.
We recorded income tax expense of $0 and $2,774,000 for the three month periods
ended March 31, 2000 and March 31, 1999 respectively.
Net income for the three months ended March 31, 2000 was $2,254,673 compared to
$4,160,719 for the three month period ended March 31, 1999. Net income per share
for the three month period ended March 31, 2000 use $0.20 basic and $0.19
diluted compared to $0.49 basic and $0.38 diluted for the three months ended
March 31, 1999.
LIQUIDITY AND CAPITAL RESOURCES
At March 31, 2000, we had $26,668,949 in cash and cash equivalents and net
working capital of $26,452,982. We believe that our cash and equivalents should
be adequate to fund our immediate needs. However, we can offer no assurances
that additional funding will not be required in the foreseeable future. All
excess cash has been invested in short-term investments.
Our assets at March 31, 2000 were $27,070,316 compared to $25,051,748 at
December 31, 1999. This increase in assets was primarily due to an increase of
cash and cash equivalents of approximately $2,004,000 as a result of cash
generated by operating activities of approximately $1,845,000 and cash provided
by financing activities of approximately $159,000. The cash generated by
operating activities was primarily from the milestone payment received from PNU.
The cash provided by financing activities resulted primarily from the exercise
of stock options that were held by our consultants.
Our liabilities at March 31, 2000 decreased to approximately $557,000 from
approximately $1,047,000 at December 31, 1999. This decrease was attributable to
a decrease in trade payables of approximately $254,000 a decrease in accrued
expenses of approximately $37,000 a decrease in accrued compensation of
approximately $234,000 and an increase in obligations under research agreements
of approximately $35,000.
We may seek to satisfy our future funding requirements through public or private
offerings of securities, with collaborative or other arrangements with corporate
partners or from other sources. Additional financing may not be available when
needed or on terms acceptable to us. If adequate financing is not available, we
may be required to delay, scale back or eliminate certain of our research and
development programs, relinquish rights to certain or our technologies, cancer
drugs or products, or license third parties to commercialize products or
technologies that we would otherwise seek to develop ourselves.
11
<PAGE>
PART II - OTHER INFORMATION
Item 1. Legal Proceedings None
Item 2. Changes in Securities None
Item 3. Defaults Upon Senior Securities None
Item 4. Submission of Matters to a Vote
of Security-Holders None
Item 5. Other Information
Effective with the opening of trading on April 14, 2000 shares of our
common stock began trading on the Nasdaq National Market under the
symbol "NEOL". Previously, shares of our Common Stock were
traded on the American Stock Exchange under the symbol "NEO". The
common stock was delisted from the American Stock Exchange effective
as of April 14, 2000. In connection with the move to the Nasdaq
National Market, we filed a Registration Statement on Form 8-A
with the Securities and Exchange Commission registering our common
stock pursuant to Section 12(g) of the Securities Exchange Act of 1934.
Item 6. Exhibits and Reports on Form 8-K None
12
<PAGE>
SIGNATURE PAGE
PURSUANT TO THE REQUIREMENTS OF THE SECURITIES EXCHANGE ACT OF 1934, THE
REGISTRANT HAS DULY CAUSED THIS REPORT TO BE SIGNED ON ITS BEHALF BY THE
UNDERSIGNED, THEREUNTO DULY AUTHORIZED.
NEOPHARM, INC.
By: /s/ Kevin M. Harris
---------------------------------
Kevin M. Harris,
CHIEF FINANCIAL OFFICER
AND AUTHORIZED OFFICER
Date: May 15, 2000
13
<TABLE> <S> <C>
<PAGE>
<ARTICLE> 5
<S> <C>
<PERIOD-TYPE> 3-MOS
<FISCAL-YEAR-END> DEC-31-2000
<PERIOD-START> JAN-01-2000
<PERIOD-END> MAR-31-2000
<CASH> 26,668,949
<SECURITIES> 0
<RECEIVABLES> 126,555
<ALLOWANCES> 0
<INVENTORY> 0
<CURRENT-ASSETS> 27,009,911
<PP&E> 165,657
<DEPRECIATION> 105,252
<TOTAL-ASSETS> 27,070,316
<CURRENT-LIABILITIES> 556,929
<BONDS> 0
0
0
<COMMON> 2,388
<OTHER-SE> 26,510,999
<TOTAL-LIABILITY-AND-EQUITY> 27,070,316
<SALES> 0
<TOTAL-REVENUES> 3,000,000
<CGS> 0
<TOTAL-COSTS> 0
<OTHER-EXPENSES> 1,158,500
<LOSS-PROVISION> 0
<INTEREST-EXPENSE> 0
<INCOME-PRETAX> 2,254,673
<INCOME-TAX> 0
<INCOME-CONTINUING> 2,254,673
<DISCONTINUED> 0
<EXTRAORDINARY> 0
<CHANGES> 0
<NET-INCOME> 2,254,673
<EPS-BASIC> .20
<EPS-DILUTED> .19
</TABLE>
